Successful First Robotics-Assisted Prostatic Artery Embolization In The UK

Successful First Robotics-Assisted Prostatic Artery Embolization In The UK

Mountain View, California-based robotics specialist Hansen Medical, Inc., recently announced the success of the first robot-assisted Prostatic Artery Embolization (PAE) in the UK, using their proprietary Magellan Robotic System. The milestone procedure was completed by Dr. Mohammad Hamady, an interventional radiologist at St. Mary’s Hospital, Imperial College, London. He utilized the Magellan 6Fr Robotic Catheter to navigate around the patient’s peripheral vasculature throughout the PAE, which was carried out to address the patient’s Benign Prostatic Hyperplasia (BPH).

“I am extremely pleased by the outcome of this initial procedure and I am excited to be able to offer this promising new treatment for a condition affecting a large number of patients,” said Dr. Hamady. “Robotic catheters offer precise control, even in these narrow and often tortuous blood vessels, which enables us to confidently offer this non-surgical option to help men suffering from the effects of prostate enlargement.”

Prostatic Artery Embolization (PAE) is a breakthrough treatment option for patients suffering from BPH that involves a non-surgical procedure, merely requiring the insertion of a catheter to ultimately help reduce blood flow to the arteries that supply the prostate. PAE is a highly recommended alternative to long-term medical treatment or more invasive procedures, as it causes minimal discomfort, downtime and risk of side effects.

Hansen’s Magellan Robotic System benchmarks robotics-assisted health procedures thanks to its Magellan Robotic Catheters that allow minimally-invasive, endovascular procedures. The system was designed to offer users procedural predictability and enhanced control and stability with the intravascular catheter. Today, more and more physicians all over the world are employing the Magellan system to address conditions like BPH, uterine fibroids, cancer and vascular disease.

“Congratulations to Dr. Hamady and the team at St. Mary’s Hospital and Imperial College London,” said Cary Vance, President and Chief Executive Officer of Hansen Medical. “The team at Imperial College have done groundbreaking work, pioneering the use of robotics for endovascular procedures performed in the peripheral vasculature. We are excited that patients in the UK suffering from BPH may now benefit from a non-surgical treatment option with the enhanced precision and predictability offered by the Magellan Robotic System.”

Leave a Comment

Your email address will not be published. Required fields are marked *